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Abstract
The emergence of multiple-drug-resistant tuberculosis (MDR-TB) has pushed our available
repertoire of anti-TB therapies to the limit of effectiveness. This has increased the urgency
to develop novel treatment modalities, and inhalable microparticle (MP) formulations are a
promising option to target the site of infection. We have engineered poly(lactic-co-glycolic
acid) (PLGA) MPs which can carry a payload of anti-TB agents, and are successfully taken
up by human alveolar macrophages. Even without a drug cargo, MPs can be potent immu-
nogens; yet little is known about how they influence macrophage function in the setting of
Mycobacterium tuberculosis (Mtb) infection. To address this issue we infected THP-1 mac-
rophages with Mtb H37Ra or H37Rv and treated with MPs. In controlled experiments we
saw a reproducible reduction in bacillary viability when THP-1 macrophages were treated
with drug-free MPs. NFκB activity was increased in MP-treated macrophages, although
cytokine secretion was unaltered. Confocal microscopy of immortalized murine bone mar-
row-derived macrophages expressing GFP-tagged LC3 demonstrated induction of autop-
hagy. Inhibition of caspases did not influence the MP-induced restriction of bacillary growth,
however, blockade of NFκB or autophagy with pharmacological inhibitors reversed this MP
effect on macrophage function. These data support harnessing inhaled PLGA MP-drug
delivery systems as an immunotherapeutic in addition to serving as a vehicle for targeted
drug delivery. Such “added value” could be exploited in the generation of inhaled vaccines
as well as inhaled MDR-TB therapeutics when used as an adjunct to existing treatments.
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Introduction
Nearly 1.5 million people die of tuberculosis (TB) annually because current vaccines and thera-
peutic regimens are inadequate. The emergence of multiple-drug-resistant TB has stretched
our existing therapeutics beyond their ability to deal with the epidemic. There is a pressing
requirement to develop new drugs and modalities that may include patient-directed therapies,
including immunotherapeutics. One promising option is to repurpose existing anti-TB agents
as cargo in advanced drug delivery systems that could also facilitate pharmaceutical develop-
ment of emerging therapeutics. One such method harnesses therapeutic aerosol bioengineering
[1] to prepare inhalable microparticles (MPs). MPs manufactured, using well-established mate-
rials, such as the US Food and Drug Administration–approved material poly(lactic-co-glycolic
acid) (PLGA), can deliver a drug cargo to the intracellular environment of phagocytes [2].
PLGA polymers are biodegradable and approved for use in a range of commercially marketed
therapeutic products. While PLGA has been widely investigated for the preparation of drug-
loaded particles for inhalation these have yet to make it to market. Much of the delay in transla-
tion of these very promising technologies lies in the lack of knowledge about the toxicological
and immunogenic effects of PLGA particles once deposited in the lungs after inhalation.
The use of inhalable delivery systems to treat TB represents an appealing alternative to tra-
ditional oral/parenteral formulations. By localising anti-tubercular therapy to the lungs, sys-
temic toxicity may be greatly decreased and with increasing local concentrations of anti-
tubercular therapy the duration of treatment may be reduced also [3, 4]. These factors com-
bined may help to improve patient compliance rates, thereby reducing the emergence of resis-
tant strains. Inhalable anti-tubercular delivery systems based on polymeric MPs have shown
great potential both in vitro and in vivo [5]. PLGAMPs are efficiently phagocytosed by human
alveolar macrophages [6, 7] and we have seen potent microbicidal effects when they carry a
payload of anti-TB drugs [8]. Although the macrophage is the effector cell in the host response
toMycobacterium tuberculosis (Mtb), it is also the niche cell for the bacillus; where Mtb can
replicate before causing cell death and moving on to infect other cells [9]. Phagocytosis of MPs
by this cell therefore provides an opportunity for targeted killing of intracellular bacilli. Such
an inhaled approach might improve the effectiveness of anti-TB therapies by reducing the fre-
quency of dosing and maximising local deposition of the anti- tubercular agent.
A key challenge in the development of inhaled MP therapies will be defining their effects, if
any, on innate and adaptive immune responses in the lung. Although a number of studies have
shown that PLGAMPs are inert [10–12] making them suitable candidates for inhalable ther-
apy, others have demonstrated that PLGA based MPs can activate endogenous macrophage
responses [13–18]. The immunogenicity of synthetic MPs is dependent on physical properties
of the particle such as size, shape, composition, surface chemistry and electrical charge, as well
as the ability of host cells to recognise them via the expression of appropriate cell surface recep-
tors. In the presence of pathogen-associated molecular patterns (PAMPs), such as LPS, poly-
meric MPs can drive important phagocyte functions, such as IL-1β [19] and TNFα production
[18] and antigen presentation [20]. Thus far some authors have suggested that they may also
support macrophage responses to Mtb infection by stimulating cytokine production and mod-
ulation of cell death pathways [16, 17, 21].
In the present study we sought to characterise the immune phenotype of macrophages fol-
lowing treatment with drug-free MPs by evaluating established pathways for endogenous mac-
rophage control of Mtb infection. To this end, we infected THP-1 macrophages with Mtb and
monitored bacillary replication in the setting of drug-free MP treatment. We found that PLGA
MPs, without a drug payload, can limit intracellular Mtb replication without altering the cyto-
kine profile produced by macrophages infected with Mtb. Treatment of uninfected cells with
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MPs did not induce the secretion of pro-inflammatory cytokines or significantly alter the via-
bility of the cells. However, MPs stimulated the activation of the NFκB pathway and autophagy
in uninfected macrophages. Inhibition of NF- κB or autophagy with pharmacological inhibi-
tors reversed the ability of MP-treated macrophages to limit Mtb growth.
Materials and Methods
Polylactide-co-glycolide (PLGA) Microparticle Manufacture and
Characterisation
Polylactide-co-glycolide (PLGA) 503H (Boehringer Ingelheim, Germany) MPs were prepared
using a double emulsion, solvent evaporation method [22]. Briefly, 50mg PLGA was dissolved
in dichloromethane (2.5% w/v) and the solution was remotely probe sonicated. A primary
emulsion (w1/o) was created by the addition of 2.5% w/v poly(vinyl) alcohol (PVA) followed
by probe sonication for 16 seconds. A final secondary emulsion (w1/o/w2) was formed by trans-
ferring the primary emulsion into a continuous phase consisting of 20ml 1% PVA. Following
homogenisation, the emulsion was mechanically stirred in the fume hood over-night to allow
the solvent to evaporate and allow microparticle formation. Microparticles were then centri-
fuged at 7,000g for 7 minutes and washed in distilled water three times to remove residual
PVA, prior to lyophilisation. Where required, the hydrophilic fluorescent dye tetramethylrho-
damine isothiocyanate (TRITC) was added to the first aqueous phase of the emulsion above
(10% w/w).
Microparticles were characterised for size by laser diffraction using a Mastersizer 2000 (Mal-
vern) for surface charge by zeta-potential (Malvern Zetasizer) and for morphology by scanning
electron microscopy (SEM) using a Tescan MIRA XMU, secondary electron detector at an
electron voltage of 5.0Kv [7].
Mycobacteria
M. tuberculosis strains H37Rv and H37Ra were obtained from the American Type Tissue Cul-
ture (Manassas, VA). Stocks were propagated in Middlebrook 7H9 medium (Difco/Becton
Dickinson, Sparks, MD) made up in low-endotoxin water (Sigma, St. Louis, MO) supple-
mented with albumin-dextrose-catalase supplement (Becton Dickinson) and 0.05% Tween 80
(Difco). Aliquots were stored at –80°C, thawed and propagated in Middlebrook 7H9 medium
to log phase before use.
Cell culture and infection
Immortalised murine bone marrow derived macrophages (BMDM) which had been stably
transfected with GFP-LC3 were a kind gift from Dr Hardy Kornfeld and Dr Michelle Hartman,
University of Massachusetts, USA [23, 24] and were maintained in DMEM containing 5μg/ml
puromycin and 10% fetal calf serum. The day before infection the cells were trypsinized and
seeded into culture dishes and 2 well Labtek chamber slides (Nunc). During and after infection
these cells were maintained in DMEM/10% fetal calf serum without puromycin.
THP-1 cells from the ATCC (TIB-202) were maintained in RPMI-1640 (GIBCO), supple-
mented with 10% foetal bovine serum (GIBCO). Prior to infection, the cells were seeded into
culture dishes and 2-well Labteks at a density of 1x105 cells /ml and differentiated using 100nM
PMA for 72 hours.
On the day of infection, log-phase bacilli were centrifuged at 2,600 x g for 10 minutes and
the bacilli were re-suspended in RPMI-1640 containing 10% foetal bovine serum. Clumps were
dispersed by passing the bacilli through a 25-gauge syringe six to eight times and the sample
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was centrifuged at 100 x g for 3 minutes to sediment any remaining clumps of mycobacteria.
To determine the amount of dispersed mycobacteria required to achieve the appropriate multi-
plicity of infection (MOI), macrophages in Labteks were treated with different amounts of
mycobacteria and incubated for 3 hours at 37°C. Extracellular bacteria where then washed off
using phosphate buffered saline and the macrophages were fixed in 2% paraformaldehyde for 5
minutes and stained for acid fast bacilli as previously described [25]. Briefly, the cells were
stained with auramine-M (Becton Dickinson), washed in distilled water and treated with the
TB-Declorizer ™. Hoescht 33342 (10μg/ml) was used to counter-stain cell nuclei and anti-fade
medium (DAKO, Glostrup, Denmark) was added before imaging. The number of bacilli per
cell was determined using an Olympus IX51 inverted fluorescent microscope (Olympus IX51,
Olympus Europa GmbH, Germany). Based on this result macrophages in culture dishes were
then infected to reach a MOI of approximately 1–5 phagocytosed bacilli per cell for 3 hours,
and then washed to remove extracellular mycobacteria. The cells were then treated for 1 hour
with 2.2μm PLGAMPs or 1.8 μm polystyrene (PS) MPs (Sigma) at a concentration of 200μg/
ml (unless otherwise stated), washed and incubated at 37°C and 5% CO2 for a total of 72 hours.
Infected cells were lysed and harvested for colony forming unit (CFU) enumeration on Mid-
dlebrook agar plates. Agar plates were incubated at 37°C and plates with a statistically relevant
number of colonies were counted between 14 and 21 days and used to calculate the number of
CFU per ml.
Confocal laser scanning microscopy (CLSM)
Immortalised BMDMs expressing GFP-LC3 were seeded in 8-well coverslip Labtek chamber
slides for live cell imaging on a confocal laser scanning microscope. The cells were treated with
2.2μm PLGAmicroparticles labelled with tetramethylrhodamine isothiocyanate (TRITC) and
the induction of autophagy was monitored. In some experiments the cells were incubated with
DQ-BSA for 2h to label lysosomes and then treated with blank (unstained) MP. For immunos-
taining, cells were fixed for 10 minutes with 2% paraformaldehyde (Sigma, St Louis, Mo), per-
meabilized for 10 minutes and incubated with antibodies to LAMP-1 (rat and anti-mouse,
clone CD107a, eBioscience) and Polyclonal Anti-Mycobacterium tuberculosis Whole Cell
Lysate minus LAM: NR13820 (obtained from BEI Resources NIAID, NIH) followed by goat-
anti Rat-Alexa-594 and goat anti-rabbit-Alexa-647 (both from Jackson Immunoresearch, Suf-
folk, UK). Coverslips were mounted on glass slides with fluorescence mounting medium. Sam-
ples were analyzed using a Zeiss LSM510 laser confocal microscope (Carl Zeiss Ltd, Welwyn
Garden City, UK) equipped with an argon (488-nm excitation line; 510 nm emission detection)
laser and a diode-pulsed, solid-state laser (excitation, 561 nm; emission, 572-nm; long-pass
filter).
Western blotting
Western blotting was carried out as previously described [25]with some modifications. Briefly,
cells were lysed in lysis buffer (50mM Tris.HCl, pH 6.8, 10% glycerol, 2% sodium dodecyl sul-
fate, 0.001% bromophenol blue, 100mMDTT, 10X protease inhibitor cocktail (Roche) and
phosphatase inhibitors (Sigma)). Samples were heated to 95°C for 10 minutes and stored at
-80°C. Lysates were subjected to SDS/PAGE on 15% Tris-Tricine Criterion (Bio-Rad, Hercules,
CA) minigels followed by transfer to 0.2-μm-pore polyvinylidene difluoride membrane
(Immun-Blot PDVF membrane; Bio-Rad). Membranes were probed with antibodies to mouse
anti-human LC3 (2G6, nanoTools Antikörpertechnik GmbH, Teningen Germany) and mouse
anti-human β–actin (Sigma). Following exposure to HRP-conjugated goat anti-mouse second-
ary antibody (Cell Signaling Technology, Danvers, MA, USA), proteins were visualized by
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enhanced chemiluminescence using Supersignal West Pico chemiluminescent substrate (Ther-
moScientific, Rockford, IL, USA).
Measurement of NFκB Activity
THP-1 XBlue™ cells (Invivogen), which are stably transfected for a reporter gene for NFκB acti-
vation, were used to assess the activation of NFκB by PLGA microparticles. THP-1 Blue cells
were cultured in RPMI-1640 with heat inactivated 10% FBS and 200μg/ml of Zeocin™. The
cells were seeded at a final density of 1 x 106 cells / ml in 96-well plates in the presence of
100nM PMA for 72 hours. The medium was changed each day for 5 days after differentiation
to remove any residual PMA, which could lead to false positive results. After 5 days the cells
were infected or treated with PLGAMPs of 0.8μm or 2.2μm and 1.8 μm PS MPs for 24 hours,
after which time 20μl of medium was added to 180μl QUANTI-Blue™ and incubated for 4
hours. The SEAP (secreted embryonic alkaline phosphatase) activity was assayed using a Wal-
lac (Perkin Elmer) plate reader at 650nm. LPS (100ng/ml) was used as a positive control for
NFκB activation.
Caspase activity assays
Fluorogenic caspase substrate assays for caspase-3/7, -8 and -9 were carried out using the sub-
strates acetyl Asp-Glu-Val-Asp 7-amido-4-methylcoumarin (Ac-DEVD-AMC), Ac-Ile-Glu-
Thr-Asp-AMC (Ac-IETD-AMC) and Ac-Leu-Glu-His-Asp-AMC (Ac-LEHD-AMC) (all from
ENZO Life Sciences) respectively. THP-1 cells were seeded at a density of 1x105 cells /ml as
described in the cell culture section and both uninfected cells and cells infected with Mtb
H37Ra (as described in the cell culture section) were treated with 2.2μmMPs for 1 hour and
then cultured for a total of 24 hours. Extracts were prepared by lysing cell pellets collected at
the indicated times in 75μl of lysis buffer (25mMHEPES (pH 7.5), 0.1% CHAPS, 1mM dithi-
threothiol) followed by 3 freeze thaw cycles at -80°C and centrifugation at 15,000g for 15 min.
Aliquots of the cleared lysates were incubated in a microtitre plate with the fluorogenic sub-
strate (final concentration of 80 μM) and incubated for 30 minutes at 37°C. Fluorescence inten-
sity was detected on a Victor plate reader (Perkin Elmer) at 360nm excitation and 460nm
emission. Samples were normalised for protein content using a BCA assay. Cells treated with
staurosporine (200ng/ml) were used as a positive control for caspase activity.
Treatment of macrophages with pharmacological inhibitors
Differentiated THP-1 cells were infected with H37Ra and then pre-treated with the pan caspase
inhibitor ZVAD-fmk (Bachem) (50μM), the NFκB inhibitor SN50 (18μM) and the PI3 kinase
inhibitor 3-MA (10mM) for 1 hour prior to treatment with 2.2μm PLGAMP. Fresh inhibitor
was added after removal of unphagocytosed particles after 48 hours. Cells were incubated at
37°C for a total of 72 hours after which they were lysed and plated for enumeration on Mid-
dlebrook agar plates.
Cytokine Secretion Assays
Supernatants from differentiated THP-1 cells with and without H37Ra infection were collected
after 24 hours and analysed according to the manufacturer’s instructions using multiplex plates
(Meso Scale Discovery) for the following 10 cytokines: IFN-γ, IL-10, IL-12 p70, IL-13, IL-1β,
IL-2, IL-4, IL-5, IL-8, TNF-α. An additional single-plex ELISA was carried out for IL-6 using
the same supernatants. The plates were read on a SECTOR Imager 2400 and analysed using
DISCOVERYWORKBENCH assay analysis software (MSD).
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Statistical Analysis
Statistical analysis was carried out using the Students t-test or One Way Analysis of Variance
followed by Tukeys Multiple Comparison test. A p-value of< 0.05 was taken to be statistically
significant.
Results
Microparticle characterisation
The MP size used in this study was chosen based on previous results that established the opti-
mal size to target alveolar macrophages both anatomically (via inhalation) and at a cellular
level (via phagocytosis) is approximately 2μm [7]. Each batch of PLGAMPs manufactured was
characterised for size, surface charge and morphology prior to further testing. The spherical
MPs produced for this study had a mean geometric diameter of 2.2 ± 0.3μm and a z-potential
of -33.4 ± 2.62 mV. When required batches of smaller 0.8 ± 0.1μmMPs were also manufac-
tured by increasing the duration of homogenisation and characterised appropriately [7].
Mycobacterial growth in macrophages is restricted by PLGA
microparticles
Previous studies have shown that poly(lactic acid) (PLA) MPs can activate macrophages and
enhance their ability to kill intracellular Mtb [26]. To determine whether MPs have an impact
on Mtb growth in macrophages, THP-1 cells, infected with H37Ra or H37Rv for 3h, were
treated with 200μg/ml of either 2.2 μm PLGAMPs or polystyrene (PS) MPs (1.8μm) for 1h,
washed and cultured for a total of 4 days. The MP size and dose were chosen based on previous
results that indicated that approximately 2 μm is the optimal size to target alveolar macro-
phages [7] and to reduce Mtb CFU by at least 5 log fold when loaded with rifampicin [8].
Treatment with drug-free PLGAMPs significantly reduced the CFU count of both strains of
Mtb compared to that of untreated cells (p<0.05). PS MPs of a similar size did not have a sta-
tistically significant effect on growth of Mtb (Fig 1).
The impact of microparticles on cell death and caspase activity
Induction of macrophage apoptosis has been demonstrated to inhibit the growth of intracellu-
lar pathogens including Mtb [27, 28] whereas necrosis is not beneficial to the host in this regard
[29]. The effect of MP treatment on macrophage viability was assessed by automated fluores-
cence microscopy using the propidium iodide exclusion assay. An initial experiment was car-
ried out to determine whether PLGA-MPs were cytotoxic; macrophages were treated with
increasing doses of MPs using the PI exclusion assay to determine the viability of the cells [25,
30]. There was no significant effect of MPs on viability until the concentration of MPs reached
1.5mg/ml (Fig 2A), which was 7.5 fold above the concentration used to inhibit Mtb growth (see
Fig 1). All further experiments were carried out using the therapeutic dose of 200μg/ml. At this
concentration of MPs the level of cell death in uninfected and Mtb infected cells was not signif-
icantly increased by treatment with PLGAMPs for 24 hours (Fig 2B).
Caspase activity is a hallmark of apoptosis. Others have shown that PLAMPs can activate
caspases in Mtb-infected macrophages [21]. In the present study the ability of PLGAMPs to
activate caspases in uninfected cells was evaluated by incubating cell lysates with fluorescently-
labelled peptide substrates for caspase-3/7, -8 and -9 respectively. No significant increases in
caspase activity were observed following treatment of macrophages with PLGAMPs alone for
24 hours (Fig 2C). To investigate whether PLGAMPs could increase the levels of apoptosis in
Mtb-infected macrophages, infected cells were treated with MPs and assayed for caspase
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activity as above. Caspase activity in Mtb-infected cells was not significantly increased by the
MPs (Fig 2C).
Activation of NFκB by PLGAmicroparticles
The potential for PLGAMPs to trigger endogenous macrophage responses was tested using a
THP-1 Blue™ cell line to evaluate their ability to activate NFκB. The results shown in Fig 3A
demonstrate that MP activation of NFκB occurred in a size dependent manner. A significant
increase in NFκB activation is observed with the 2.2μmMPs (p<0.05). PS MP also activated
NFkB (S1 Fig).
Cytokine secretion profile of microparticle-treated macrophages
NFκB plays a pivotal role in innate immune signalling; its activation via TLR receptors can
lead to the upregulation of a network of pro- and anti-inflammatory cytokine genes. These
cytokines can influence intracellular growth of Mtb; for example, both TNF and IL-1β play a
protective role in Mtb infection contributing to the bactericidal activity of macrophages
whereas IL-10 promotes Mtb survival by preventing phagosome-lysosome fusion [31]. To
determine whether PLGAMPs could induce cytokine secretion of uninfected THP-1 cells or
alter the cytokine profile of Mtb-infected cells, THP-1 cells were untreated or treated with MPs
as before. After 24h the medium was removed and a secretion profile of 11 cytokines was deter-
mined by MSD ELISA. Treatment of THP-1 macrophages with 2.2μmMPs did not result in
any increase in cytokine secretion above background levels (Fig 3B). As expected, macrophages
infected with Mtb secreted a range of pro and anti-inflammatory cytokines including IL-1β,
TNF, IL-6 and IL-10 (Fig 3B). However, PLGAMP treatment did not alter the cytokine profile
of Mtb-infected macrophages (Fig 3B). Levels of IL-2, IL-4, IL-5 and IL-13 were unaltered by
infection in the presence or absence of Mtb.
Fig 1. Drug-free PLGAMPs restrict the growth of Mtb in macrophages. PMA differentiated THP-1 cells were infected with (A) H37Ra or (B) H37Rv to
reach an MOI of 1–5 phagocytosed bacilli per cell. The cells from several wells were lysed and serial dilutions were plated on Middlebrook 7H10 agar plates
to determine the bacterial load at 3h (Mtb 3h). Cells in the remaining wells were left untreated (Mtb) or treated with 2.2μmPLGAMPs (Mtb+PLGA) or 1.8 μm
polystyrene (PS) MPs (Mtb+PS) for 1 hour at 37°C, 5% CO2 after which the cells were washed and incubated for a further 72 hours. The cells were then
lysed, combined with the medium and serial dilutions plated on Middlebrook 7H10 agar plates. The plates were incubated at 37°C for 14–21 days and colony
forming units were counted. Results are expressed as mean +/- SEM, * p< 0.05 compared to untreated Mtb-infected cells. NS = not significant compared to
untreated Mtb-infected cells.
doi:10.1371/journal.pone.0149167.g001
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Induction of autophagy by PLGAmicroparticles
Autophagy is a mechanism whereby cells recycle cellular components by enclosing them in
autophagosomes that fuse with lysosomes to mediate degradation of their contents. Autophagy
also plays a role in host defence by engulfing and degrading microbes [32]. Mtb has evolved to
arrest phagosome maturation by targeting PI3-kinase signalling and Rab-GTPases [33]. How-
ever, induction of autophagy, by starvation or rapamycin treatment, can overcome the phago-
lysosomal maturation block to degrade intracellular mycobacteria [34]. To test the ability of
MPs to induce autophagy, immortalised murine BMDM stably expressing GFP- LC3 were
treated with PLGAMPs and analysed by confocal microscopy. A lipidated form of LC3,
LC3-II, is a marker of autophagosomes. In the absence of MPs the cells displayed diffuse cyto-
plasmic GFP staining with occasional puncta present. Live cell imaging showed accumulation
of GFP- LC3 around MPs as they were being phagocytosed (Fig 4A and S1 Movie). PS MP also
co-localized with GFP-LC3 (S1 Fig) in agreement with previously published results [35].
Although the formation of LC3-positive vesicles could be seen to occur during phagocytosis
of MPs, quantitative analysis of puncta at various times after the addition of MPs did not reveal
a significant difference in the number of puncta per cell compared to untreated cells. This sug-
gests that the association of LC3 and MPs is transient and that LC3 positive phagosomes may
fuse with lysosomes causing degradation of GFP- LC3 by hydrolytic enzymes. DQ-Red-BSA is
a substrate of acidic hydrolases and a marker for lysosomes in live cells. After approximately 2
Fig 2. The effect of MPs on cell death and caspase activity in the presence or absence of Mtb infection. (A) PMA-differentiated THP-1 cells were
treated with PLGAMPs at the indicated doses for 1 hour. The cells were washed to remove extracellular MPs and incubated for a total of 24 hours at 37°C,
5% CO2. Cell death was measured by propidium iodide exclusion assay and automated fluorescence microscopy. (B) THP-1 cells were uninfected or
infected with Mtb (H37Ra) to reach an MOI of 1–5 phagocytosed bacilli per cell, washed and treated with 2.2μmPLGAMPs for 1 hour at 37°C, 5% CO2 after
which the cells were washed and incubated for a total of 24 hours. Cell death was measured as above. (C) In parallel experiments cell lysates were assayed
for caspase activity using caspase substrates coupled to AMC and proteolytic cleavage of the substrates was measured on a microplate reader (Ex/
Em = 360/460nm). Staurosporine (0.4μg/ml) was used as a positive control for apoptosis. Results are expressed as arbitrary fluorescence units (mean +/-
SEM) and are representative of 3 independent experiments, * p< 0.05 compared to uninfected cells.
doi:10.1371/journal.pone.0149167.g002
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hours MPs had trafficked to DQ-Red-BSA positive lysosomes, the majority of which were not
positive for GFP-LC3 (Fig 4B).
To determine whether autophagic flux was taking place macrophages were incubated with
PLGAMPs for 3 hours in the presence of the vacuolar H+ ATPase inhibitor bafilomycin A1
which prevents acidification of lysosomes or vehicle (DMSO). There was a significant differ-
ence in the proportion of PLGAMP associated with GFP-LC3 in bafilomycin A1-treated cells
compared to cells which were untreated (Fig 5C).
PLGA-MPs triggers autophagic flux in Mtb-infected macrophages
To assess the role of autophagy in PLGA-induced anti-mycobacterial activity of macrophages,
Mtb-infected cells were incubated with PLGA-MP and examined by confocal microscopy after
Fig 3. PLGAMPs activate NFkB but do not stimulate pro-inflammatory cytokine secretion by macrophages. (A) THP-1 XBlue™ cells were
differentiated with PMA for 72h and the medium was changed for several days before treatment. Cells were then treated with 0.8μm or 2.2μmPLGAMPs at
the indicated concentrations for 1 hour. Extracellular MPs were washed off and the cells were incubated at 37°C for a total of 24 hours. Supernatants were
analysed for the presence of SEAP by means of a substrate reaction and the absorbance was measured at 650nm on a microplate plate reader to determine
NFkB activation. Results shown are means +/1 SEM for three independent experiments. LPS (100ng/ml) treatment was used as a positive control for NFκB
activation. (B) THP-1 cells were incubated with media alone (media) or infected with Mtb H37Ra for 3 hours. The cells were then washed to remove
extracellular mycobacteria and were treated for 1 hour with 200μg/ml MPs. After washing to remove extracellular MPs the cells were cultured for a total of 24
hours after which supernatants were assayed for cytokine levels using MSDmultiplex assays. Cytokine levels are reported as mean +/- SEM and are
representative of three independent experiments performed in triplicate, * p< 0.05 compared to untreated control.
doi:10.1371/journal.pone.0149167.g003
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24 hours (Fig 6A. The number of GFP-LC3 positive Mtb phagosomes was similar in untreated
cells and those treated with PLGA-MP (Fig 6B). However, there was a significant increase in
the number of GFP-LC3 positive phagosomes that were positive for the late endosomal/lyso-
somal marker LAMP-1 in macrophages treated with PLGAMP (Fig 6C).
Blocking autophagy and NFκB reverses the inhibition of Mtb growth by
microparticles
We next investigated the mechanism by which infected macrophages treated with PLGAMPs
achieved a reduction in Mtb growth using pharmacological inhibitors. As previous results had
shown that these MP delivery systems could induce NFκB activation (Fig 3A), a peptide
Fig 4. PLGAMPs co-localise with LC3 following phagocytosis by macrophages. Live confocal microscopy images of immortalized murine BMDMs
expressing GFP-LC3 were acquired using a ×63 oil objective following incubation with (A) TRITC-loaded MPs (red) for 3h, or (B) pre-loaded with DQ-Red-
BSA for 2 hours to visualize lysosomes, washed, rested for 1 hour in medium without DQ-Red-BSA and then incubated with blank PLGAMPs (200μg/ml) for
1h. The white arrows indicate localization of GFP-LC3 with MPs, blue arrows indicate localization of lysosomes with MPs. The results shown are
representative of five independent experiments.
doi:10.1371/journal.pone.0149167.g004
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inhibitor of NFκB, SN50, was used to test whether MPs could reduce Mtb viability when NFκB
was inhibited. To confirm that SN50 inhibits NFκB activity THP-1 XBlue™ cells were incubated
with the inhibitor and stimulated with LPS. As expected, LPS-induced NFκB activity was
reduced in SN50-treated cells. Caspase activity was inhibited using the pan-caspase inhibitor
zVAD.fmk to assess if cell death or inflammasome activation contributed to this mechanism.
The effectiveness of zVAD.fmk at inhibiting caspase activity was confirmed by its ability to
inhibit staurosporine-induced caspase 3/7 activity in THP-1 macrophages (S2 Fig). Finally, the
PI3-kinase inhibitor 3-MA was used to inhibit autophagy. Inhibition of autophagy by 3-MA
was confirmed by its ability to prevent the formation of LC3-positive puncta caused by uptake
of zymosan particles (S2 Fig). As reported above (Fig 1A) macrophages infected with H37Ra
and treated with PLGAMPs harboured significantly less Mtb 72 hours after the initial infection
compared to untreated infected cells. In the presence of the caspase inhibitor z-VAD-fmk the
MPs were still able to reduce Mtb CFU in a significant manner (p<0.05). Conversely, both
NFκB and autophagy inhibition resulted in the inability of the MPs to reduce intracellular Mtb
growth, indicating that both of these pathways play a role in the control of Mtb proliferation by
macrophages (Fig 7A). As expected, there was no detectable increase in LC3-II protein levels in
PLGAMP-treated cells above those of untreated cells when macrophage lysates were subjected
to western blotting Fig 7B, lane 4). However, SN50 inhibited lipidation of LC3-I to LC3-II in
PLGAMP-treated macrophages infected with Mtb (Fig 7B) suggesting that NFκB stimulates
autophagy in Mtb-infected cells in the presence of PLGA-MP.
Discussion
In this study we have shown that treatment of infected macrophages with 2.2μm PLGAMPs
significantly reduces the intracellular burden of Mtb, while polystyrene MPs of a similar size
did not. We hypothesised that PLGAMPs might augment the bactericidal activity of macro-
phages by activating innate immune pathways in macrophages as was previously demonstrated
for PLAMPs [16, 26]. To test this hypothesis we examined the effect of PLGAMPs on a num-
ber of innate immune defence pathways including cell death, NFκB activity, cytokine secretion
and autophagy. The bactericidal activity of the MPs was not associated with the induction of
Fig 5. PLGAMPs phagocytosis triggers autophagic flux in macrophages. (A) Immortalized murine BMDMs expressing GFP-LC3 incubated with
PLGA-MP for 3 hours in the presence of bafilomycin A1 (30nM) or vehicle (DMSO) were subjected to immunofluorescent staining for LAMP-1 and imaged by
confocal microscopy to determine (B) the proportion of PLGAMP co-localising with GFP-LC3 which are reported as mean +/- SEM.of three independent
experiments, * p< 0.05. The white arrows indicate localization of GFP-LC3 with PLGAMPs. LAMP1 staining was included to aid in the visualization of MP
phagosomes.
doi:10.1371/journal.pone.0149167.g005
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cell death or significant alterations in caspase activity. Nor did treatment of macrophages with
MPs stimulate the secretion of inflammatory cytokines in the absence of infection or signifi-
cantly alter the cytokine profile of Mtb-infected macrophages. However, phagocytosis of MPs
was associated with activation of innate immune pathways as evidenced by increased activation
of NFκB and the induction of autophagy. Inhibition of autophagy and NFκB abrogated the
bactericidal effect of PLGAMPs in macrophages.
There has been much debate in the literature as to whether PLGAMPs are biologically
active in the absence of a drug load with some studies showing that they are inert [10–12] while
others have shown potent biological effects [13–18, 26, 36]. Indeed differential effects might be
expected depending on the size, morphology and route of exposure of the particles. We there-
fore focused our studies (specifically for their application in inhaled treatment of Mtb) on
PLGA particles of a very specific size and morphology (required for inhalation and cellular tar-
geting) in relevant airway cells. NFkB is a master regulator of innate immune signalling path-
ways driving increased expression of pro-inflammatory genes such as NLRP3, TNF and IL-1β.
In the present study, treatment with PLGAMPs increased NFkB activity in uninfected THP-1
Fig 6. PLGAMPs trigger autophagic flux in Mtb-infected macrophages. Immortalized murine BMDMs expressing GFP-LC3 were infected with Mtb
H37Ra at an MOI of 1–5 phagocytosed bacilli per cell followed by treatment with PLGAMP as before. (A) After a total of 24 hours, infected macrophages
were fixed and stained with anti-LAMP1_and anti-Mtb antibodies, and then observed by laser scanning confocal microscopy. The proportion of (B) LC3
positive Mtb phagosomes and (C) LC3 positive phagosomes which were also positive for LAMP1 were counted. Data represent the mean +/- SEM of three
independent experiments in which more than 100 phagosomes were counted for each condition. *P < 0.05. The white arrows indicate localization of Mtb
phagosomes with GFP-LC3, blue arrows indicate co-localization of Mtb, GFP-LC3 and LAMP1. The results shown are the means of three independent
experiments.
doi:10.1371/journal.pone.0149167.g006
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cells. This is in agreement with a previous study which demonstrated that 5–7μm PLGAMPs
activate NFkB in murine J774 macrophages [36]. However, in contrast to that and several
other previously published reports [14–18, 26, 36], we found that PLGAMPs did not induce
the secretion of either pro- or anti-inflammatory cytokines by uninfected macrophages. In
addition, treatment with MPs did not significantly alter the cytokine profile of Mtb-infected
macrophages ruling out a synergistic enhancement of TLR-mediated cytokine production by
polymeric MPs in these cells [19]. These variations in outcome may be due to differences in
particle size, composition or the responding cell lines. Despite its failure to drive cytokine
secretion in THP-1 macrophages, inhibition of NFkB reversed the anti-mycobacterial effect of
MPs, indicating that it plays a role in this process. NFkB activity regulates other stress-response
pathways in macrophages including the modulation of autophagic flux. Indeed, in the present
study inhibition of NFkB led to a reduction in the levels of LC3-II in infected macrophages
treated with PLGAMP suggesting that it drives autophagy in this setting. The role that NFkB
plays in autophagy is cell and context-dependent and the interplay between these two pathways
is quite complex [37]. In the setting of mycobacterial infection, NFkB can drive increased
expression of DNA-regulated autophagy modulator 1 (DRAM1) which is required for the initi-
ation of anti-mycobacterial autophagy and promotes the fusion of autophagosomes with lyso-
somes [38]. Further investigation will be required to determine the mechanism of NFkB
activation by PLGAMPs and its role in activating anti-mycobacterial pathways.
The induction of canonical autophagy by starvation or rapamycin treatment of Mtb-
infected macrophages enhances their ability to control intracellular Mtb growth by overcoming
a block in phagolysosomal maturation [34]. There is substantial evidence that biopersistent
nanoparticles can cause autophagy [39] but little is known about the interaction of biodegrad-
able MPs with the autophagic pathway. Phagocytosis of polystyrene MPs involves a non-
canonical form of autophagy termed LC3-dependant phagocytosis (LAP) which results in
translocation of LC3 to the phagocytic cup and the formation of single-membrane autophago-
somes, in the presence [40] or absence of TLR agonists [35]. LAP links phagocytosis of
Fig 7. Blocking autophagy or NFkB activity interferes with killing of Mtb in PLGA PLGAMP-treated macrophages. (A) PMA-differentiated THP-1 cells
were untreated or pre-incubated with inhibitors (50μM zVAD.fmk, 10mM 3-MA or 10μMSN50) vehicle (DMSO) for 1 hour and then infected for 3 hours with
H37Ra at an MOI of 1–5 phagocytosed bacilli per cell. Extracellular mycobacteria were washed and the cells were incubated with 2.2 μmPLGAMPs (200μg/
ml) for 1 hour followed by washing to remove extracellular MPs. The cells were then incubated for a total of 72 hours after which CFU were determined by
serial dilution on Middlebrook agar plates. * p< 0.05 compared to untreated (for MPs) or DMSO (for zVAD-fmk). NS = not significant compared to untreated
cells. (B) Induction of LC3-II in macrophages infected with H37RaMtb. Macrophages were infected with Mtb for 3 hours and treated with PLGAMP in the
presence or absence of SN50 for a further 3 hours. Whole-cell lysates were subjected to SDS-PAGE, followed by western blot analysis using the indicated
antibodies.
doi:10.1371/journal.pone.0149167.g007
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synthetic particles by scavenger receptors such as MARCO (which can mediate the uptake of
PLGAMPs in vivo) [13] to innate immune activation pathways in APCs [41]. We observed
transient GFP-LC3 co-localization with particles during phagocytosis of PLGAMPs after
which MPs trafficked to lysosomes. In addition, treatment with PLGAMPs increased autopha-
gic flux in macrophages infected with H37Ra. Furthermore, the PI3-kinase inhibitor 3-MA
abrogated the anti-mycobacterial activity induced by PLGAMPs, confirming a role for autop-
hagy in this process. A detailed analysis of the autophagy pathway induced by PLGAMPs will
be required to establish whether there is a link between LAP and the restriction of Mtb growth.
Our study has several limitations which should be kept in mind when interpreting the
results. Firstly, although we show that PLGAMPs inhibited the growth of H37Ra and H37Rv,
our mechanistic results on the involvement of autophagy and NFkB activity were obtained
with the attenuated H37Ra strain of Mtb and may not apply to the macrophage response to vir-
ulent strains, However, both H37Ra and H37Rv inhibit phagosome acidification which can be
overcome by inducers of autophagy [34]. Therefore, it seems reasonable to assume that PLGA
MPs could have similar effects in macrophages infected with virulent H37Rv. Secondly,
although non-biodegradable PS MPs also activated NFkB and triggered LAP in macrophages,
they did not significantly affect intracellular growth of Mtb. The reasons for this are not clear
but may be related to the different physico-chemical properties of these two materials. While
polystyrene is inert and non-biodegradable, PLGA is hydrolysed to lactic and glycolic acid
monomers which can be further catabolised via the tricarboxylic acid cycle. It is possible that
PLGA or its metabolites influence innate immune pathways, in ways which are not yet clear, to
contribute to the microbicidal activity of infected macrophages.
In addition to their potential use in inhaled therapies for TB, there is increasing interest in
the use of biodegradable engineered particles for other biomedical applications. Polymeric MPs
have been tested as delivery vehicles for subunit vaccines in order to improve their immunoge-
nicity. As well as directly killing intracellular pathogens, autophagy also plays an important
role in antigen presentation via the MHC-I and MHC-II pathways. Synthetic MPs are particu-
larly efficient at cross priming antigen specific CD8+ T cells, which are important in defence
against intracellular pathogens [42] and a target of anti-cancer vaccines [43]. This may be due
in part to delivery of the antigen and adjuvant to the same endosomal compartment [44]. How-
ever, several studies have demonstrated that antigens encapsulated in PLGAMPs elicit more
potent immunogenic responses than the corresponding soluble formulations [44, 45] even in
the absence of an adjuvant [46]. Autophagy induced by PLGAMPs may contribute to the adju-
vant effect of MPs in vivo by promoting LAP to enable efficient phagocytosis and subsequent
delivery to endosomes and/or improve processing of antigens for presentation on MHC
molecules.
Macrophage apoptosis restricts the intracellular survival of mycobacteria [47]. Yadev et al
observed increased caspase activity and cell death in Mtb infected macrophages treated with
PLAMPs [21]. PLGAMPs have also been shown to cause caspase-3-dependent apoptosis of
circulating inflammatory monocytes in mouse models of inflammation [13]. In the present
study we found that PLGAMPs did not cause a significant increase in caspase activity or
induce apoptosis of either uninfected or infected macrophages at a dose at which they effec-
tively inhibit Mtb growth. The lack of effect of the pan-caspase inhibitor zVAD-fmk on Mtb
growth confirmed that apoptosis did not play a significant role in the ability of PLGAMPs to
modulate Mtb replication in macrophages. This does not rule out the possibility that higher
concentrations of PLGAMPs, which we found caused a significant amount of cell death (Fig
2A), could mediate mycobacterial killing by triggering apoptosis or another form of cell death.
While further long term testing is needed to fully evaluate the effects of MPs on inflamma-
tory and immune pathways post inhalation, the results herein provide important information
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on the response of airway cells to inhaled PLGAMPs. This information is critical for the scien-
tific, clinical and regulatory communities if the full potential of these advanced drug delivery
systems is to be realised. Taken together our data indicate that 2.2μm PLGAMPs do not pro-
mote an inflammatory response from macrophages or lead to excessive cell death. They do,
however, support the anti-mycobacterial activity of Mtb infected macrophages by inducing
autophagy. This autophagy-inducing property of MPs acting in synergy with their anti-tuber-
cular chemotherapeutic cargo may contribute to the efficacy of inhaled MPs in the treatment
of TB.
Supporting Information
S1 Fig. PS-MP induce NFkB activation and autophagy. (A) NFkB activation was determined
in the presence of PS-MP in THP-1 X Blue™ cells by measuring secreted embryonic alkaline
phosphatase activity and (B) GFP-LC3 positive puncta (green) induced by PS-MP in the pres-
ence of Bafilomycin A1 (30nM) were visualised in live BMDB using an epifluorescence micro-
scope (Olympus).
(TIF)
S2 Fig. Validation of the efficacy of inhibitors. (A) Caspase 3/7 activity was measured in
THP-1 macrophages the presence of the apoptotic inducer staurosporine (stauro) with or with-
out zVAD.fmk (50μm). (B) NFkB activation by LPS (100ng/ml) in THP-1 XBlue™ cells was
determined in the presence or absence of SN50 (18μM) by measuring secreted embryonic alka-
line phosphatase activity in triplicate ( p< 0.05 compared to LPS alone) and (C) GFP-LC3
positive puncta (green) induced in BMDM by zymosan in the presence or absence of 3-MA
(10mM), were visualised using an epifluorescence microscope (Olympus). Nuclei were counter
stained with Hoechst 33358.
(TIF)
S3 Fig. Full scan of LC3 western blot shown in Fig 7B.
(TIF)
S4 Fig. Full scan of β-actin western blot shown in Fig 7B.
(TIF)
S1 Movie. Co-localization of PLGAmicroparticle phagosomes with GFP-tagged LC3. Time
lapse movie of immortalized murine BMDM expressing GFP-tagged LC3 showing phagocyto-
sis of TRITC-labelled PLGAMPs. Time-lapse confocal images were obtained using a laser-
scanning confocal microscope (LSM710; Carl Zeiss). Frames were taken every 12.6 s for 4 min.
(AVI)
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